RECEF (Recce Pharmaceuticals) YoY EPS Growth: 110.81% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RECEF Recce Pharmaceuticals Ltd RECEF
18 GF Score
Price $0.22
! 5 Warning Signs
View Full Analysis

What is Recce Pharmaceuticals YoY EPS Growth?

Recce Pharmaceuticals RECEF 18 YoY EPS Growth is 110.81% as of Jun. 2026. GuruFocus rates RECEF with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Recce Pharmaceuticals's YoY EPS Growth for the quarter that ended in Jun. 2026 was 110.81%.

Recce Pharmaceuticals's Earnings per Share (Diluted) for the six months ended in Jun. 2026 was $0.00.

Recce Pharmaceuticals YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Recce Pharmaceuticals's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recce Pharmaceuticals YoY EPS Growth Chart

Recce Pharmaceuticals Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.85 -13.95 -34.69 10.61 38.98

Recce Pharmaceuticals Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -153.33 25.00 2.63 -80.95 110.81
RECEF
18GF Score
Recce Pharmaceuticals Ltd RECEF
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recce Pharmaceuticals YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Recce Pharmaceuticals's YoY EPS Growth for the fiscal year that ended in Jun. 2026 is calculated as:

YoY EPS Growth (A: Jun. 2026 )
=(Earnings per Share (Diluted) (A: Jun. 2026 )-Earnings per Share (Diluted) (A: Jun. 2025 ))/ | Earnings per Share (Diluted) (A: Jun. 2025 ) |
=(-0.036--0.059)/ | -0.059 |
=38.98 %

Recce Pharmaceuticals's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(0.004--0.037)/ | -0.037 |
=110.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 110.81% mean?
Recce Pharmaceuticals (RECEF) has a YoY EPS Growth of 110.81% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Recce Pharmaceuticals and its competitors.
Is Recce Pharmaceuticals' YoY EPS Growth too high?
Recce Pharmaceuticals' current YoY EPS Growth is 110.81%. Overall, Recce Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Recce Pharmaceuticals' YoY EPS Growth compare to VRTX and REGN?
Recce Pharmaceuticals' YoY EPS Growth of 110.81% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Recce Pharmaceuticals and its competitors. Recce Pharmaceuticals's current YoY EPS Growth is 110.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recce Pharmaceuticals stock overvalued right now?
Recce Pharmaceuticals (RECEF) has a current YoY EPS Growth of 110.81%. The current YoY EPS Growth is 110.81%. Recce Pharmaceuticals' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Recce Pharmaceuticals (RECEF), the current YoY EPS Growth is 110.81% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Recce Pharmaceuticals Business Description

Other Exchanges R9Q:GermanyRCE:Australia
Address 3 Brodie Hall Drive, Suite 10, Technology Park, Bentley, WA, AUS, 6102
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
18GF Score

Get the complete analysis for RECEF

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.22
Price